Retrospective Study Includes 636 Patients with Refractory Aggressive
Non-Hodgkin Lymphoma from Four Major Institutional Databases
Findings Highlight Need for New Therapeutic Options as Patients
Achieved Only a 7 Percent Complete Response Rate and Median Overall
Survival of 6.3 Months with Currently Available Therapies
SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today
highlighted the publication of the first large-scale multi-institutional
analysis of outcomes of patients with refractory aggressive non-Hodgkin
lymphoma (NHL) in the latest electronic edition of BLOOD. The
study, SCHOLAR-1 (Retrospective
Non-Hodgkin Lymphoma Research),
showed outcomes in patients with refractory aggressive NHL subtypes
including diffuse large B-cell lymphoma (DLBCL), transformed follicular
lymphoma (TFL) or primary mediastinal B-cell lymphoma (PMBCL) following
treatment with currently available therapies:
Objective response rate of 26 percent
Complete response rate of 7 percent
Median overall survival of 6.3 months
These findings highlight the unmet medical need and provide an important
benchmark for studies that address this refractory patient population.
"SCHOLAR-1 demonstrates the uniformly poor treatment outcomes for
patients with aggressive non-Hodgkin lymphoma and emphasizes the need
for breakthrough therapies for these refractory patients," said
Christian Gisselbrecht, MD, Professor of Hematology, Saint Louis
Hospital at Diderot University Paris 7, and corresponding author of the
study. "Although 60 to 70 percent of non-Hodgkin lymphoma patients
survive five years after rituximab-based chemotherapy and autologous
stem cell transplant, nearly half of them either do not respond or
relapse shortly after transplant. SCHOLAR-1 provides a rigorous measure
of outcomes for these patients who do not benefit from currently
available therapies, and this landmark study will serve as an important
historical control for evaluating new therapeutic candidates in the
field of non-Hodgkin lymphoma."
Key points and findings:
SCHOLAR-1 uses pooled, patient-level data from two of the largest
randomized controlled studies in NHL, the Canadian Cancer Trials Group
study Ly.12 and the Lymphoma Academic Research Organization (LYSARC)
Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study, and
from two observational cohorts from MD Anderson Cancer Center and the
Molecular Epidemiology Resource of the University of Iowa/Mayo Clinic
Lymphoma Specialized Program of Research Excellence (IA/MC).
The analysis includes 636 patients who met criteria for refractory
DLBCL, TFL and PMBCL. Refractory status was defined as progressive
disease or stable disease as best response to last chemotherapy, or
relapse ≤12 months post-ASCT.
While patients with relapsed/refractory NHL, a more broadly defined
patient population studied in Ly.12 and CORAL, have heterogeneous
outcomes to subsequent therapy, the subgroup of patients with strictly
refractory NHL, as studied in SCHOLAR-1, have uniformly poor outcomes
and greater unmet need.
In the refractory NHL patient pool studied in SCHOLAR-1, objective
response rate was 26 percent, complete response rate was 7 percent,
and median overall survival was 6.3 months.
Outcomes for the refractory NHL patient pool studied in SCHOLAR-1 were
consistently poor across patient subgroups.
SCHOLAR-1 was funded through an unrestricted grant from Kite.
Kite is a biopharmaceutical company engaged in the development of
innovative cancer immunotherapies with a goal of providing rapid,
long-term durable response and eliminating the burden of chronic care.
The company is focused on chimeric antigen receptor (CAR) and T cell
receptor (TCR) engineered cell therapies designed to empower the immune
system's ability to recognize and kill tumors. Kite is based in Santa
Monica, CA. For more information on Kite, please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the potential to
advance improved therapeutic options to treat aggressive NHL. Various
factors may cause differences between Kite's expectations and actual
results as discussed in greater detail in Kite's filings with
the Securities and Exchange Commission, including without limitation in
its Form 10-Q for the quarter ended March 31, 2017. Any forward-looking
statements that are made in this press release speak only as of the date
of this press release. Kite assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005818/en/
SVP, Corporate Communications
& Investor Relations
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media